Oratonin™ is a derivative of salmon calcitonin that is absorbed in the gastroinstestinal tract after oral administration. Like calcitonin, it is an agonist for the calcitonin receptor, which is most notably found on the surface of osteoclasts. Thus, Oratonin helps to maintain bone integrity by limiting bone resorption. Potential indications could include osteoporosis, Paget’s disease, and related maladies. Oratonin has completed Phase 1 studies and is ready for Phase 2.